PURE Bioscience Reports Fiscal 2023 Financial Results
PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal year ended July 31, 2023.
- PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobial, today reported financial results for the fiscal year ended July 31, 2023.
- Net loss for the fiscal year ended July 31, 2023 was ($4.0 million), compared to ($3.5 million) for the fiscal year ended July 31, 2022.
- Net loss, excluding share-based compensation, for the fiscal year ended July 31, 2023 was ($3.6 million), compared to ($2.9 million) for the fiscal year ended July 31, 2022.
- Net cash used in operations for the fiscal year ended July 31, 2023 was ($3.3 million), compared to ($2.5 million) for the fiscal year ended July 31, 2022.